Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/08—Drugs for disorders of the urinary system of the prostate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/10—Antioedematous agents; Diuretics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
  • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Definitions

• the present invention relates to a pharmaceutical composition in tablet form, containing an active ingredient, used for administration once a day.
• the conventional sustained-release dosage forms are hardly suitable for certain active principles which have an absorption window in the upper parts of the gastrointestinal tract, that is to say which are absorbed in the stomach, the upper parts. small intestine, duodenum, jejunum and ilium, and less or less at the colonic level. Indeed, the conventional administration unit releases the active substance throughout its passage in the gastrointestinal tract and not only in the part where the absorption of the active ingredient is maximum.
• the present invention relates to a pharmaceutical composition in tablet form containing an active ingredient, used for administration once a day, overcoming the disadvantages mentioned above.
• the invention is characterized in that in contact with the gastric fluid, the pharmaceutical composition rapidly increases its volume. It is indeed clearly advantageous that this composition increases its volume not only considerably but also very rapidly, as soon as it comes into contact with the gastric fluid. This makes it possible to ensure a longer residence time of this pharmaceutical composition in the stomach, to avoid premature gastric emptying and thus to ensure that most of the active ingredient contained in the pharmaceutical composition is released and absorbed. in the portion of the gastrointestinal tract where the absorption capacity is highest.
• An object of the invention is a pharmaceutical composition under form of a matrix tablet, comprising an active ingredient, and allowing a prolonged release of the latter, which after fifteen minutes in contact with a representative medium of the gastric fluid rapidly increases in volume, with a swelling rate of at least 200 %, more particularly at least 250%.
• matrix tablet is meant a pharmaceutical composition for oral administration containing an active substance dispersed uniformly in one or more suitable excipients which, after compression, allow the formation of a matrix capable of controlling the release of the active principle.
• representative medium of the gastric fluid is meant a 0.01 M aqueous solution of hydrochloric acid and 0.1 M sodium chloride at 37 ° C.
• the rate of swelling of the tablets is determined by measuring the thickness and the diameter of the dry tablet and the tablet remained fifteen minutes immersed in the representative medium of the gastric fluid and using a suitable measuring instrument.
• the degree of swelling (in percent) can thus be expressed in terms of thickness, diameter or volume, according to the following formulas:
• Vto Volume of the tablet at TO
• Seen 5 Volume of the tablet at 15 minutes. the volume of the tablet being calculated according to the following formula
• D is the tablet diameter
• e is the thickness of the tablet wafer
• h is the half difference between the total tablet thickness and the wafer thickness
• R is the tablet radius of curvature.
• the pharmaceutical composition is in the form of a single-phase matrix tablet.
• the pharmaceutical composition is in the form of a matrix tablet having at least two phases.
• the pharmaceutical composition may comprise one or more active ingredients in one or more phases.
• the pharmaceutical composition will more particularly comprise one or two active subtances.
• phase is meant a homogeneous mixture of one or more excipients, in the form of a powder or granule, which may contain an active ingredient.
• a pharmaceutical composition according to the invention comprising two or more phases may be in the form of a multi-layer tablet (bilayer, tri-layer, etc.), more particularly a bilayer, or in the form of a core. covered with one or more phases.
• the invention consists of a pharmaceutical composition in the form of a gastric residence matrix tablet comprising an active ingredient, and at least one phase containing, at least, as excipients: a) povidone and / or polyvinyl acetate in proportions ranging from 30 to 80% by weight of the phase,
• crospovidone may be replaced or combined with another super-disintegrant such as low-substituted hydroxypropylcellulose (L-HPC), sodium carboxymethyl starch and / or croscarmellose sodium.
• L-HPC low-substituted hydroxypropylcellulose
• sodium carboxymethyl starch sodium carboxymethyl starch
• croscarmellose sodium another super-disintegrant
• the matrix tablet according to the invention has the advantage of swelling very quickly in contact with gastric fluids. Indeed, the presence of excipients a), b) and c) in the proportions according to the invention makes it possible to obtain a synergy of swelling. The tablet could thus reside for several hours in the stomach.
• the matrix compound comprises at least two phases, one or more of the phases may comprise an active ingredient.
• each phase may have an identical or different composition in excipients of another phase, it being understood that at least one of the phases comprises the excipients a), b) and c) in the proportions as indicated according to the invention.
• one of the phases does not include the excipients a), b) and c), each in the proportions as indicated according to the invention, the skilled person can determine its composition according to the biopharmaceutical requirements, such as control release of the active ingredient, increased swelling rate.
• povidone and polyvinyl acetate excipients or the povidone / polyvinyl acetate mixture are commercially available or, more particularly, the mixture is chosen from those sold under the name Kollidon® SR.
• the povidone and / or the polyvinyl acetate are in an amount ranging from 30 to 80% by weight of the phase containing it and more particularly from 30 to 65%.
• Crospovidone is a crosslinked homopolymer of ⁇ -vinyl-2-pyrrolidinone of molecular weight greater than 1,000,000DA. This polymer belongs to the category of super-disintegrants, able to quickly and intensively capture the surrounding liquid.
• crospovidone sold commercially under the name Kollidon® CL (BASF) or Plasdone® XL (ISP).
• Hydroxypropylcellulose is a low-substituted hydroxypropyl ether of cellulose, insoluble in water and alcohols but capable of swelling in these solvents.
• L-HPC LH-11 grade provided by Shin Etsu.
• Sodium carboxymethyl starch or sodium starch glycolate is the sodium salt of a carboxymethyl starch ether. There are three grades, A, B and C, which differs in sodium content. By way of example, mention may be made of sodium starch glycolate sold under the trade name Primojel® (Avebe) or Explotab® (JRS Pharma).
• Croscarmellose sodium is a cellulosic polymer obtained by crosslinking carmellose sodium.
• Ad-Di-Sol® Ad-Di-Sol®
• Crospovidone or super-disintegrants such as low-substituted hydroxypropylcellulose, sodium carboxymethyl starch or sodium starch glycolate, croscarmellose sodium, are present in an amount ranging from 5 to 25% by weight of the phase containing them and more particularly of
• the carbomer is a polymer of acrylic acid crosslinked with an allyl ether of sucrose or pentaerythritol having a very high molecular weight (of the order of one million).
• Carbopol® 974 or Carbopol® 71G NOVEON
• Carbopol® 71G which makes it possible to obtain aqueous dispersions having a viscosity of between 4000 and 11000 cps (dispersion at 0.5%).
• the carbomer is in the tablet or in a phase in proportions in an amount ranging from 5 to 40% by weight respectively of the tablet or the phase and more particularly from 10 to 35%.
• the excipients a), b) and c) are respectively in amounts of 40 to 70% for povidone and / or polyvinyl acetate, 10 to 20% for crospovidone and 10 to 30% for the carbomer.
• the tablet may also include any suitable excipient necessary for the manufacture of the tablet, such as:
• soluble or insoluble diluents microcrystalline cellulose, lactose, mannitol, dicalcium phosphate, etc.
• insoluble diluents in an amount ranging from 5 to 30% by weight of the phase containing it;
• lubricants magnesium stearate, talc, hydrogenated castor oil, PEG 6000, glycerol behenate, stearic acid, etc.
• flow agents colloidal silica, precipitated silica, etc.
• compositions according to the invention may for example be useful for benzamides and ⁇ 1 -antagonists, as well as the following active ingredients: captopril, furosemide, ursodesoxycholic acid, amoxicillin, (+) - ⁇ - aminomethyl-2-methoxysulfonamidobenzenemethanol (disclosed in patent application EP 842 148 to Example 3.6) or 3'- (2-amino-hydroxyethyl) -4'-fluoromethanesulfonanilide (NS 49).
• the benzamides are in particular metoclopramide, veralipride, alizapride, and clébopride, especially in amisulpride, tiapride, sulpiride and their salts.
• ⁇ 1 -antagonists are in particular terazosin and alfuzosin and their salts, in particular alfuzosin hydrochloride. They are intended in particular for the treatment of benign prostatic hypertrophy.
• Captopril is used especially for the treatment of hypertension, furosemide as a diuretic, arnoxicillin and its salts as an antibiotic, and ursodesoxycholic acid and its salts is used for the treatment of cholelithiases, hepatic disorders and syphilis.
• Benzamides, ⁇ 1-antagonists are also covered, including their mixtures, in particular their racemic mixtures, but also their salts.
• active ingredients which are more particularly suitable for the compositions according to the invention, mention may be made of amisulpride (D) -tartrate, (S) - (-)
• the amount of active ingredient in the pharmaceutical composition is generally from 0.1 mg to 200 mg.
• the tablets of the invention can be produced by direct compression of a mixture of powders or by granulation and compression using the usual production technologies.
• the chosen compression format can be optimized according to the general knowledge of the skilled person.
• the working compression force varies between 500 DaN and 3000 DaN so as to obtain tablets with a tensile strength that allows them to be handled and administered without any problem (between 80 and 300N for 10R10 mm tablets, for example) . Obtained, according to the methods to be described in more detail in the examples, mono tablets, or at least two phases having a shape that allows easy administration and swallowing.
• each phase of the tablet may have a different thickness ranging from 1 to 8 mm, but preferably from 2 mm to 6 mm. These dimensions may vary depending on the compression format.
• Example 1 Preparation of a monolayer tablet comprising 10 mg of alfuzosin hydrochloride
• the tablets described in this example are obtained by direct compression using a Forgerais OA alternative compression machine.
• the rate of swelling of the tablets is determined by measuring the thickness and the diameter of the dry tablet and the tablet which has been left for 15 minutes immersed in gastric liquid at 37 ° C. (0.01 M HCl + 0.1 M NaCl), and this using a suitable measuring instrument.
• the swelling ratio is 80% by thickness and 25% by diameter, ie about 200% by volume.
• the release profile an active ingredient in the gastric medium (pH2 + 0.1 M NaCl) obtained with this formulation is a profile of order 0 is: - 10 to 20% released in 1 hour.
• the tablets described in this example are obtained by direct compression using a Forgerais OA alternative compression machine. - Beforehand, all the excipients are sieved (1 mm grid) and then mixed using a Turbula® mixer. The mixture flows freely and facilitates the filling of the compression chamber.
• the swelling rate of the tablets is determined by the method described above.
• the swelling is 80% in thickness and 30% in diameter, ie about 300% by volume.
• the release profile an active ingredient in the gastric medium (pH2 + 0.1 M NaCl) obtained with this formulation is a profile of order 0 is: - 10 to 20% released in 1 hour.
• Example 3 Preparation of a bi-layer tablet comprising 10 mg of alfuzosin hydrochloride
• the tablets described in this example are obtained by direct compression using a Forgerais OA alternative compression press. - Beforehand, all the excipients are sieved (1 mm grid) and then mixed using a Turbula® inversion mixer. The mixture flows freely, thus facilitating the filling of the compression chamber.
• the swelling rate of the tablets is determined by the method described above. In this example, the swelling is 300% by volume.
• the tablets described in this example are obtained by direct compression using a Forgerais OA alternative compression press. Beforehand, all the excipients are sieved (1 mm grid) and then mixed using a Turbula ® inverting mixer. The mixture flows freely, thus facilitating the filling of the compression chamber.
• the swelling rate of the tablets is determined by the method described above in Example 1. In this example, the swelling is 350% by volume.
• Example 5 Preparation of a 500 mg two-layer tablet comprising 10 mg of alfuzosin hydrochloride
• the tablets described in this example are obtained by direct compression using a Forgerais OA alternative compression press. - Beforehand, all the excipients are sieved (1 mm grid) and then mixed using a Turbula® inversion mixer. The mixture flows freely, thus facilitating the filling of the compression chamber.
• Flow of the mixture ⁇ 10 seconds per 100g of mixture.
• Hardness of the tablets 150N. Mass of the tablets: 500 mg. Tablet size: 12R12 mm.
• the swelling rate of the tablets is determined by the method described above. In this example, the swelling is 360% by volume.
• the tablets described in this example are obtained by direct compression using a Forgerais OA alternative compression press. - Beforehand, all the excipients are sieved (1 mm grid) and then mixed using a Turbula® inversion mixer. The mixture flows freely, thus facilitating the filling of the compression chamber.
• the swelling rate of the tablets is determined by the method described above. In this example, the swelling is. 2Z0 ._% by volume.
• Example 7 Preparation of a bi-layer tablet comprising 10 mg of alfuzosin hydrochloride
• the tablets described in this example are obtained by direct compression using a Forgerais OA alternative compression press. - Beforehand, all the excipients are sieved (1 mm grid) and then mixed using a Turbula® inversion mixer. The mixture flows freely, thus facilitating the filling of the compression chamber.
• the swelling rate of the tablets is determined by the method described above. In this example, the swelling is 300% by volume.
• the tablets described in this example are obtained by direct compression using a Forgerais OA alternative compression press.
• the swelling rate of the tablets is determined by the method described above. In this example, the swelling is 300% by volume.
• Examples 9 and 10 below show single-layer monosaccharide tablet compositions. These compositions can be used as a swelling placebo layer in the manufacture of multilayer tablets. It is also possible to incorporate the active ingredient in these compositions, for example at a height of 10 mg, in order to obtain a pharmaceutical composition according to the invention.
• Example 9 Preparation of a 500 mg monolayer placebo tablet.
• the tablets described in this example are obtained by direct compression using a Forgerais OA alternative compression press.
• the swelling rate of the tablets is determined by the method described above. In this example, the swelling is 340% by volume.
• Example 10 Preparation of a 500 mg monolayer placebo tablet.
• the tablets described in this example are obtained by direct compression using a Forgerais OA alternative compression press. - Beforehand, all the excipients are sieved (1 mm grid) and then mixed using a Turbula® inversion mixer. The mixture flows freely, thus facilitating the filling of the compression chamber.
• the swelling rate of the tablets is determined by the method described above. In this example, the swelling is 470% by volume.
• Example 11 Preparation of a tri-layer tablet of 700 mg containing 10 mg of alfuzosin hydrochloride.
• the tablets described in this example are obtained by direct compression using a Forgerais OA alternative compression press. - Beforehand, all the excipients are sieved (1 mm grid) and then mixed using a Turbula® inversion mixer. The mixture flows freely, thus facilitating the filling of the compression chamber.
• the swelling rate of the tablets is determined by the method described above.
• the swelling is 104% in thickness, 41% in width and 36% in length.

Landscapes

• Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Physiology (AREA)
• Nutrition Science (AREA)
• Gastroenterology & Hepatology (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Oncology (AREA)
• Urology & Nephrology (AREA)
• Communicable Diseases (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Apparatuses For Bulk Treatment Of Fruits And Vegetables And Apparatuses For Preparing Feeds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=34950702

Family Applications (1)

Country Status (23)

Families Citing this family (8)

Citations (1)

Family Cites Families (17)

• 2004
  • 2004-08-19 FR FR0408986A patent/FR2874325B1/fr not_active Expired - Fee Related
• 2005
  • 2005-08-04 PE PE2005000906A patent/PE20060639A1/es not_active Application Discontinuation
  • 2005-08-16 AR ARP050103428A patent/AR050696A1/es not_active Application Discontinuation
  • 2005-08-17 BR BRPI0514532-5A patent/BRPI0514532A/pt not_active IP Right Cessation
  • 2005-08-17 AU AU2005276307A patent/AU2005276307B2/en not_active Ceased
  • 2005-08-17 WO PCT/FR2005/002092 patent/WO2006021692A1/fr active Application Filing
  • 2005-08-17 NZ NZ553673A patent/NZ553673A/en not_active IP Right Cessation
  • 2005-08-17 MX MX2007001957A patent/MX2007001957A/es active IP Right Grant
  • 2005-08-17 CN CN2005800311527A patent/CN101022808B/zh not_active Expired - Fee Related
  • 2005-08-17 UY UY29073A patent/UY29073A1/es not_active Application Discontinuation
  • 2005-08-17 EP EP05798249A patent/EP1781295A1/fr not_active Withdrawn
  • 2005-08-17 EA EA200700217A patent/EA012981B1/ru not_active IP Right Cessation
  • 2005-08-17 JP JP2007526512A patent/JP5048492B2/ja not_active Expired - Fee Related
  • 2005-08-17 MY MYPI20053859A patent/MY145832A/en unknown
  • 2005-08-17 KR KR1020077003897A patent/KR20070046124A/ko not_active Application Discontinuation
  • 2005-08-17 CA CA2577361A patent/CA2577361C/fr not_active Expired - Fee Related
  • 2005-08-18 TW TW094128210A patent/TWI357329B/zh not_active IP Right Cessation
• 2007
  • 2007-02-04 IL IL181150A patent/IL181150A0/en unknown
  • 2007-02-16 US US11/675,712 patent/US20070190140A1/en not_active Abandoned
  • 2007-02-19 ZA ZA2007/01443A patent/ZA200701443B/en unknown
  • 2007-03-09 NO NO20071315A patent/NO20071315L/no not_active Application Discontinuation
  • 2007-03-14 MA MA29756A patent/MA28862B1/fr unknown
• 2008
  • 2008-02-13 HK HK08101572.6A patent/HK1112575A1/xx not_active IP Right Cessation

Patent Citations (1)

Also Published As

Similar Documents

Legal Events